Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures FTSE (0.16%), DAX (0.41%), CAC40 +0.08%

Jun 11 ,2025

  • Synopsis

    • European equity markets are set for a mixed open amidst higher Asian equities Wednesday as markets process in-principal agreement between US and China. Hang Seng extending bull run with mainland stocks gaining. Japan, Korea, Australia and Taiwan all firming. S&P 500 futures declining afterhours.

    • UK MPs questions on Wales at 11:30BST and weekly PMQs at 12noon, Chancellor Reeves to announce results of government's second phase of its spending review setting out day-to-day departmental budgets until 2028/29 and capital departmental budgets until 2029/30, and after which, the Sustainable Aviation Fuel Bill continues its passage through parliament. In Germany, there's conf of interior ministers (through Fri).

    • Polish NPs due to hold vote of confidence called by PM Tusk. Järvaveckan 2025 (one of Sweden's most important events for socially engaged businesses, associations, authorities, politicians, and citizens) (through Sat) and 20th Brussels Forum (through Thu). UK Ofcom's CEO Dawes speaks at 11:30BST at London Tech Week. VivaTech summit (through Sat) sees keynote speech at 11:00CET by Nvidia's CEO and Sanofi's (SAN.FP) CEO panellist at 12:10. Event speakers also includes LVMH's (MC.FP) CEO Arnault (9:30 on Thu)

    • In central banks, Bank of Finland and SUERF conf on Monetary policy implementation; speakers include BOE's Saporta at 7:30BST. ECB's Buch speech at 11:00CET at Goldman Sachs European Financials Conf. There's Central Banking Summer Meetings (through Thu), speaker include BOE's Mills at 10:15BST and 15:30; Bank of Spain's Núñez panellist at 16:15. ECB's Lane presentation at 11:30CET at 2025 Government Borrowers Forum in Dublin (Mon-Wed), BOE's Benjamin speech at 11:00BST at the Global investment management summit and ECB's Cipollone video message at 14:00CET at the European Payments Council's General Assembly. Central bank of Ireland publishes its latest Financial Stability Review, whilst governor Makhlouf before parliamentary committee at 15:30BST on Israeli Bond Program. Bank of Latvia's Krasovska participates in the "Global Government Fintech Lab 2025" conf in Dublin.

    • A light macro front sees Belgium Apr industrial production.

    • In earnings, Inditex (ITX.SM) reported Q1 net income €1.31B vs StreetAccount €1.28B and said store and online sales in c.FX between 1-May and 9-Jun increased +6%. Outokumpu (OUT1V.FH) issued a CMD update presenting financial targets for 2026-2030 including EBITDA run-rate improvement of €250M. Fnac Darty (FNAC.FP) presents its 2030 strategic plan and objectives: operating margin >3% by 2030, nearly 4 million subscribers for all services combined by 2030. In M&A, Demant (DEMANT.DC) announced it will acquire KIND Group for total consideration of €700M (~ DKK 5.2B) on cash- and debt-free basis, suspending its share buyback and keeping FY25 outlook unchanged

  • Politics/Macro/World News

    • US progress on deals with India, Mexico; appeals court leaves Trump tariffs in effect:

  • Top company news

    • Earnings/updates

      • Benelux:

        • FLOW.NA (Flow Traders) -- reports May market statistics

      • France:

        • FNAC.FP (Fnac Darty) -- presents its 2030 strategic plan and objectives: operating margin >3% by 2030, nearly 4 million subscribers for all services combined by 2030

      • Nordics:

        • DEMANT.DC (Demant) -- to acquire KIND Group for total consideration of €700M (~ DKK 5.2B) on cash- and debt-free basis; suspends share buyback; FY25 outlook unchanged

        • OUT1V.FH (Outokumpu) -- CMD update: presents financial targets for 2026-2030 including EBITDA run-rate improvement of €250M

        • BIOVIC.B.SS (Biovica International) -- targets FY25 revenue SEK8.5M vs FactSet SEK10M [2 est, SEK9-11M]

      • Southern Europe:

        • ITX.SM (Inditex) -- reports Q1 net income €1.31B vs StreetAccount €1.28B; store and online sales in c.FX between 1-May and 9-Jun increased 6%

    • M&A

      • KTCG.AV (Kapsch TrafficCom) -- divests majority shareholding in and ceded control of Kapsch Telematic Services IOOO, Belarus; remains substantially economically entitled to its business success

      • MMB.FP (Lagardere) -- Vivendi reports it acquired 11.3M Lagardere shares for €24.10/share 5-Jun

      • DEMANT.DC (Demant) -- to acquire KIND Group for total consideration of €700M (~ DKK 5.2B) on cash- and debt-free basis; suspends share buyback; FY25 outlook unchanged

      • FAE.SM (FAES Farma) -- to acquire SIFI, S.p.A.

      • SYNSAM.SS (Synsam) -- Holder Theia Holdings (CVC Capital Partners) to place ~24.4M shares in Synsam AB via DNB Carnegie and SEB

      • BYW6.GR (BayWa) -- sells Cefetra to First Dutch for ~€125M

      • SESG.FP (SES) -- European Commission approves unconditionally the acquisition of Intelsat by SES

      • EQT.SS (EQT AB) -- EQT expected to put Icon Group on the block - The Australian

      • BAMI.IM (Banco BPM) -- UniCredit expected to win EU antitrust approval for Banco BPM acquisition after offering to divest 206 branches - Reuters

      • PHIL.IM (Philogen) -- subsidiary Philochem enter into agreement to license OncoACP3 worldwide rights to RayzeBio for up to $1.35B plus royalties

      • APOTEA.SS (Apotea) -- Holders to place ~8.8M shares in Apotea AB via DNB Carnegie and SEB

      • SCANFL.FH (Scanfil) -- expands in Northern US by acquiring 80% of ADCO Circuits for $15.5M

      • Scania in talks with other investors to form consortium to acquire Northvolt's R&D laboratory - FT, citing CEO

    • Healthcare

      • ALCJ.FP (Crossject) -- reports progresses in the development of ZEPIZURE Junior

      • CANTA.SS (Cantargia) -- nadunolimab antibody awarded US FDA Fast Track Designation

      • UCB.BB (UCB) -- announces BIMZELX (bimekizumab) three-year data at EULAR 2025

    • Other

      • AFRY.SS (AFRY) -- signs 5-year SEK 150-200M p.a. agreement with BAE Systems Hägglunds

      • ORK.NO (Orkla) -- announces Orkla India has filed draft red herring prospectus in connection with proposed IPO

      • ALL.LN (Atlantic Lithium Limited) -- CEO Keith Muller accepts temporary 10% salary reduction; Neil Herbert to step down as Executive Chairman and become Non-Executive Chairman

      • PUB.FP (Publicis Groupe) -- awarded Mars' $1.7B media business from WPP; Interpublic to hand Mars' global PR - AdWeek

      • TEF.SM (Telefonica) -- pledges to invest in data centres and cyber security services in the hope it will help secure regulatory approval for M&A in Europe - FT

      • DHL.GR (DHL Group) -- announces plans to invest more than €500M in the Middle East

      • AENA.SM (Aena S.M.E.) -- receives approval for expansion of Josep Tarradellas Barcelona-El Prat Airport

  • Key rating changes

    • Upgrades

      • QLT.LN (Quilter) -- buy from neutral at UBS

      • BNP Paribas Exane upgrades DEMANT.DC; downgrades SOON.SW

      • Kepler Cheuvreux upgrades BAYN.GR, YAR.NO; downgrades TESB.BB

      • FAE.SM (FAES Farma) -- buy from neutral at JB Capital Markets

      • Barclays upgrades KOJAMO.FH; downgrades GRI.LN

      • BAYN.GR (Bayer AG) -- to buy from hold at HSBC

      • CNE.LN (Capricorn Energy) -- to hold from sell at Stifel (earlier, timing uncertain)

    • Downgrades

      • DB1.GR (Deutsche Börse) -- to neutral from buy at UBS

    • Initiations

      • WISE.LN Wise Plc initiated neutral at Cantor Fitzgerald

  • Data

    • Nikkei +0.48% to 38394.10

    • Hang Seng +0.90% to 24380.41

    • Shanghai Composite +0.54% to 3402.94

    • S&P futures (19.3) vs prior close of 6045.0

    • €-$ (0.0001) or (0.01%) to 1.1425

    • $-¥ +0.09 or +0.06% to 144.98

    • €-¥ +0.07 or +0.04% to 165.60

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE